Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Humphrey Fonge

18PUBLICATIONS
52CO-AUTHORS
Aboriginal and Torres Strait Islander mathematical, physical and chemical sciences (excl. astronomy and cosmology)Molecular targetsMining engineeringPharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

Sort by Publication Date:
|Jul 15, 2026
Correction: Sekar et al. Concussion/Mild Traumatic Brain Injury (TBI) Induces Brain Insulin Resistance: A Positron Emission Tomography (PET) Scanning Study. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 9005.

|Apr 07, 2026
Potency and safety of novel [<sup>225</sup>Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.

Jessica Pougoue Ketchemen, Alissar Monzer, Fabrice Ngoh Njotu

|Jan 16, 2026
[<sup>225</sup>Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.

Anjong Florence Tikum, Dede Api Fon, Fabrice Ngoh Njotu

|Dec 22, 2025
Preclinical characterization of 3p-C-DEPA<sub>-NCS</sub> and 3p-C-DEPA<sub>-TFP</sub>-PEG<sub>4</sub> as potential Actinium-225 bifunctional chelators using DOTA<sub>-NCS</sub> and macropa<sub>-NCS</sub> as benchmarks.

Jessica Pougoue Ketchemen, Stephen Ahenkorah, Emmanuel Nwangele

|Mar 24, 2025
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.

Anjong Florence Tikum, Nikita W Henning, Jessica Pougoue Ketchemen

|Dec 13, 2024
Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.

Jessica Pougoue Ketchemen, Fabrice Ngoh Njotu, Hanan Babeker

Pageof 3

Frequent Collaborators

3 joint publications

Hanan Babeker

3 joint publications

Jessica Pougoue Ketchemen

2 joint publications

Alissar Monzer

2 joint publications

Clarence Ronald Geyer

2 joint publications

Viswas Raja Solomon

2 joint publications

Elahe Alizadeh

2 joint publications

Changiz Taghibiglou

2 joint publications

Emmanuel Nwangele

2 joint publications

Maruti Uppalapati

2 joint publications

Fabrice Ngoh Njotu

Frequent Collaborators

3 joint publications

Hanan Babeker

3 joint publications

Jessica Pougoue Ketchemen

2 joint publications

Alissar Monzer

2 joint publications

Clarence Ronald Geyer